VC  Apple Tree Partners

     Office Locations:

47 Hulfish Street, Suite 441
Princeton, NJ 08542
Phone: 609-751-5375
Fax: 609-921-2156



  • Early
  • Seed



  • Life Sciences & Healthcare



    Since 1999, Apple Tree Partners (ATP) has worked with entrepreneurs to found and build drug and medical device companies. ATP founds the companies in which it invests, committing capital to participate as a major investor in all financing rounds. ATP executives are deeply involved with the ATP portfolio, serving as acting CEOs, COOs, CSOs and Board or Executive Chairmen. With this active investment approach, ATP has created one of the top IRRs in the life sciences venture industry. The firm currently manages three venture capital funds with committed capital totaling $235 million. ATP intends to devote the entirety of its third fund, ATP III, capitalized currently at $100 million, to create a start-up pharmaceutical company. The goal is to combine the pragmatism of venture-backed company creation with the sophistication and resources of pharmaceutical R&D organizations. To facilitate this project, ATP is working with one of its offshore limited partners who has committed an additional $200 million to the pharmaceutical company start-up endeavor; these funds are being reserved for late-stage development, and for asset acquisition, once the initial pipeline is in place. Assets in-licensed to create the ATP III portfolio will be developed by the firm's in-house, wholly-owned pharmaceuticals research and development contract research organization, Apple Tree Pharmaceuticals, Inc.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Aaron Kantoff Associate
    Behshad Sheldon Venture Partner
    David McIntyre Partner
    Diane M. Daych Partner
    Frank Young MD, PhD Venture Partner


    Recent Funding Events (trailing 12 months):







      Akero Therapeutics



      Series B


      Stoke Therapeutics



      Series B


      Akero Therapeutics



      Series A


    Portfolio companies include:

      Aileron Therapeutics
        web link

      Akero Therapeutics
        web link

      Braeburn Pharmaceuticals
        web link

        web link

      Corvidia Therapeutics
        web link

        web link

      Elstar Therapeutics
        web link

      Gloucester Pharmaceuticals
        web link

        web link

      ROX Medical
        web link

      Stoke Therapeutics
        web link

        web link

        web link

      Tokai Pharmaceuticals
        web link

        web link


    Recent News: